Compare CCCC & OPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCCC | OPTX |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | United States | United States |
| Employees | N/A | 164 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 330.3M |
| IPO Year | 2020 | N/A |
| Metric | CCCC | OPTX |
|---|---|---|
| Price | $3.73 | $7.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 452.4K |
| Earning Date | 05-06-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.69 | $1.18 |
| 52 Week High | $5.17 | $14.92 |
| Indicator | CCCC | OPTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 44.86 |
| Support Level | $3.42 | $6.39 |
| Resistance Level | $3.91 | $8.77 |
| Average True Range (ATR) | 0.22 | 0.72 |
| MACD | 0.00 | 0.16 |
| Stochastic Oscillator | 47.46 | 56.95 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Syntec Optics Holdings Inc is vertically integrated from design and component manufacturing for lens system assembly to imaging module integration for system solutions. Making its tools, molding, and nano machining allows close interaction and recut ability, enabling special techniques to hold tolerances to sub-micron levels. It has steadily developed a variety of other complementary manufacturing techniques to provide a wide suite of horizontal capabilities including thin film deposition coatings, glass molding, polymer molding, tool-making, mechanical manufacturing, and nano machining. Syntec Optics focuses on four end markets of defense, medical, consumer, and communications all with several mission-critical applications.